Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.

Chung Sang TseE V LoftusL E RaffalsA A GossardAmy L Lightner

Published in: Alimentary pharmacology & therapeutics (2018)

Current evidence suggests that biological therapies used for the treatment of IBD are not effective treatments for PSC. Further study is needed to elucidate any potential beneficial effect of adalimumab on PSC.

Keyphrases

ulcerative colitis
oxidative stress
rheumatoid arthritis
risk assessment
systemic lupus erythematosus
climate change
human health
disease activity